Evidence map›Paper›PMID 32116262›Full record

ArticleJournal of Parkinson's disease2020

Neurophysiological Biomarkers of Parkinson's Disease.

Shani Waninger, Chris Berka, Marija Stevanovic Karic, Stephanie Korszen, P David Mozley, Claire Henchcliffe, Yeona Kang, Jacob Hesterman, Tomer Mangoubi, Ajay Verma

Open access · hybridAbstract read
In one paragraph

Article in Journal of Parkinson's disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Roles of Glia in Synapse Nano-organization.Advances in neurobiology · 2026
    Review
  8. Article
  9. Review
  10. Review
  11. Personal and Family Perspectives Regarding Neurodegenerative Disorder Risk.Journal of community medicine & public health · 2026
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Shani WaningerAdvanced Brain Monitoring Inc., Carlsbad, CA, USA.
Chris BerkaAdvanced Brain Monitoring Inc., Carlsbad, CA, USA.
Marija Stevanovic KaricAdvanced Brain Monitoring Inc., Carlsbad, CA, USA.
Stephanie KorszenAdvanced Brain Monitoring Inc., Carlsbad, CA, USA.
P David MozleyWeill Cornell Medical College, New York, NY, USA.
Claire HenchcliffeWeill Cornell Medical College, New York, NY, USA.
Yeona KangWeill Cornell Medical College, New York, NY, USA.
Jacob HestermanInviCRO, Boston, MA, USA.
Tomer MangoubiInviCRO, Boston, MA, USA.
Ajay VermaCodiak BioSciences, Cambridge, MA, USA.
Advanced Brain Monitoring (United States) · USCornell University · USInvicro (United States) · US

Funding

Multi-site longitudinal Integrated Neurocognitive and Sleep-Behavior Profiler for the Endophenotypic Classification of Dementia Subtypes (INSPECDS)R44AG050326 · NIA · ADVANCED BRAIN MONITORING, INC. · PI BERKA, CHRIS · 2016 to 2024
$4.4M
Characterizing Alzheimer's Disease with INSPECDS: Integrated Neurocognitive and Sleep-Behavior Profiler for the Endophenotypic Classification of Dementia SubtypesR44AG054256 · NIA · ADVANCED BRAIN MONITORING, INC. · PI BERKA, CHRIS · 2017 to 2018
$1.1M
NIA NIH HHS R44 AG050326NIA NIH HHS R44 AG054256
6 · The paper itself

Abstract

backgroundThere is a need for reliable and robust Parkinson's disease biomarkers that reflect severity and are sensitive to disease modifying investigational therapeutics.

objectiveTo demonstrate the utility of EEG as a reliable, quantitative biomarker with potential as a pharmacodynamic endpoint for use in clinical assessments of neuroprotective therapeutics for Parkison's disease.

methodsA multi modal study was performed including aquisition of resting state EEG data and dopamine transporter PET imaging from Parkinson's disease patients off medication and compared against age-matched controls.

resultsQualitative and test/retest analysis of the EEG data demonstrated the reliability of the methods. Source localization using low resolution brain electromagnetic tomography identified significant differences in Parkinson's patients versus control subjects in the anterior cingulate and temporal lobe, areas with established association to Parkinson's disease pathology. Changes in cortico-cortical and cortico-thalamic coupling were observed as excessive EEG beta coherence in Parkinson's disease patients, and correlated with UPDRS scores and dopamine transporter activity, supporting the potential for cortical EEG coherence to serve as a reliable measure of disease severity. Using machine learning approaches, an EEG discriminant function analysis classifier was identified that parallels the loss of dopamine synapses as measured by dopamine transporter PET.

conclusionOur results support the utility of EEG in characterizing alterations in neurophysiological oscillatory activity associated with Parkinson's disease and highlight potential as a reliable method for monitoring disease progression and as a pharmacodynamic endpoint for Parkinson's disease modification therapy.

Indexed as

Beta RhythmBiomarkersElectroencephalography Phase SynchronizationAgedDopamine Plasma Membrane Transport ProteinsElectroencephalographyFemaleHumansMachine LearningMaleMiddle AgedOutcome Assessment, Health CareParkinson DiseasePositron-Emission TomographyBiomarkersDopamine Plasma Membrane Transport ProteinsBiomarkersdopamine transporter PETEEGneurophysiologyParkinson’s disease

Identifiers

PMID32116262
PMCPMC7242849
OpenAlexW3006866383

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.